21, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the company will host a virtual webcast: “LX9211 - Changing the Paradigm for Treatment of ...

Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on LXRX stock, giving a Buy rating yesterday.Invest with Confidence: ...

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases.

Needham analyst Joseph Stringer maintained a Hold rating on Lexicon Pharmaceuticals (LXRX – Research Report) today. The company’s shares closed ...

Lexicon Pharmaceuticals reaffirmed its plans to seek approval for Zynquista (sotagliflozin) as an adjunct treatment to insulin in type 1 diabetes (T1D) and chronic kidney disease (CKD) as part of ...

Lexicon Pharmaceuticals ... a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The ...

Over the last four quarters, the company has surpassed consensus EPS estimates two times. Lexicon, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.7 ...

THE WOODLANDS, Texas, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the company will host a virtual webcast: “LX9211 - Changing the Paradigm ...